We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
- Authors
Pitisuttithum, Punnee; Rerks-Ngarm, Supachai; Bussaratid, Valai; Dhitavat, Jittima; Maekanantawat, Wirach; Pungpak, Swangjai; Suntharasamai, Pravan; Vanijanonta, Sirivan; Nitayapan, Sorachai; Kaewkungwal, Jaranit; Benenson, Michael; Morgan, Patricia; O'Connell, Robert J; Berenberg, Jeffrey; Gurunathan, Sanjay; Francis, Donald P; Paris, Robert; Chiu, Joseph; Stablein, Donald; Michael, Nelson L; Excler, Jean-Louis; Robb, Merlin L; Kim, Jerome H
- Abstract
A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of 31.2% for prevention of HIV acquisition in HIV-uninfected adults participating in a community-based efficacy trial in Thailand.
- Publication
PloS one, 2011, Vol 6, Issue 12, pe27837
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0027837